MindMed Closes Acquisition of HealthMode, a Leading Machine Learning Digital Medicine Company

Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital…

MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company

Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital…

MindMed’s LSD Neutralizer Study Begins

Potential Emergency Off-Switch for Psychedelic Assisted Therapies BASEL, Switzerland, Feb. 17, 2021 /CNW/ — MindMed (NEO: MMED), (OTCQB: MMEDF),…

MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds

ZUG, Switzerland, Feb. 11, 2021 /PRNewswire/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company announced…

MindMed Streamlines Leadership with Further Emphasis on Integrating Psychedelic Drug Development with Digital Medicines and Therapeutics

J.R. Rahn to become sole CEO; Perry Dellelce to become Chair; Stephen Hurstretires as executive but remains on board; Stanley…

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

BASEL, Switzerland, Jan. 20, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company,…

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14,…

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and…

MindMed Announces $50 Million Bought Deal Public Offering

NEW YORK, Dec. 14, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the…

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

Provides Clinical Development Update on 18-MC Based on positive pre-IND meeting with U.S. Food and Drug…

MindMed Announces $25 Million Bought Deal Public Offering

NEW YORK, Nov. 25, 2020 /CNW/ – Mind Medicine (MindMed) Inc. (NEO: MMED) (OTCQB: MMEDF) (“MindMed” or the…

MindMed to Launch Albert, A Digital Medicine Division for Psychedelic Medicines

NEW YORK, Nov. 24, 2020 /CNW/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine…